Biblio
Export 2657 results:
Author [ Title
Filters: First Letter Of Last Name is S [Clear All Filters]
“Utility of an Alzheimer's Disease Risk-Weighted Polygenic Risk Score for Predicting Rates of Cognitive Decline in Preclinical Alzheimer's Disease: A Prospective Longitudinal Study.”, J Alzheimers Dis, vol. 66, no. 3, pp. 1193-1211, 2018.
, “Utility of Molecular and Structural Brain Imaging to Predict Progression from Mild Cognitive Impairment to Dementia.”, J Alzheimers Dis, vol. 60, no. 3, pp. 939-947, 2017.
, “The Utility of the Cognitive Function Instrument (CFI) to Detect Cognitive Decline in Non-Demented Older Adults.”, J Alzheimers Dis, vol. 60, no. 2, pp. 427-437, 2017.
, “The Utilization of Retinal Nerve Fiber Layer Thickness to Predict Cognitive Deterioration.”, J Alzheimers Dis, vol. 49, no. 2, pp. 399-405, 2016.
, “The Utilization of Retinal Nerve Fiber Layer Thickness to Predict Cognitive Deterioration.”, J Alzheimers Dis, vol. 49, no. 2, pp. 399-405, 2016.
, “The Utilization of Robotic Pets in Dementia Care.”, J Alzheimers Dis, vol. 55, no. 2, pp. 569-574, 2017.
, “Vacuolar Protein-Sorting Proteins Are Reduced Even Before Cognitive Decline in a Mouse Model of Alzheimer's Disease.”, J Alzheimers Dis, vol. 96, no. 3, pp. 1011-1017, 2023.
, “Validation by Magnetic Resonance Imaging of the Diagnostic Potential of a Heptapeptide-Functionalized Imaging Probe Targeted to Amyloid-β and Able to Cross the Blood-Brain Barrier.”, J Alzheimers Dis, vol. 60, no. 4, pp. 1547-1565, 2017.
, “Validation by Magnetic Resonance Imaging of the Diagnostic Potential of a Heptapeptide-Functionalized Imaging Probe Targeted to Amyloid-β and Able to Cross the Blood-Brain Barrier.”, J Alzheimers Dis, vol. 60, no. 4, pp. 1547-1565, 2017.
, “Validation of a Commercial Chemiluminescence Immunoassay for the Simultaneous Measurement of Three Different Amyloid-β Peptides in Human Cerebrospinal Fluid and Application to a Clinical Cohort.”, J Alzheimers Dis, vol. 54, no. 2, pp. 691-705, 2016.
, “Validation of a Commercial Chemiluminescence Immunoassay for the Simultaneous Measurement of Three Different Amyloid-β Peptides in Human Cerebrospinal Fluid and Application to a Clinical Cohort.”, J Alzheimers Dis, vol. 54, no. 2, pp. 691-705, 2016.
, “Validation of a Latent Construct for Dementia in a Population-Wide Dataset from Singapore.”, J Alzheimers Dis, vol. 55, no. 2, pp. 823-833, 2017.
, “Validation of a Latent Construct for Dementia in a Population-Wide Dataset from Singapore.”, J Alzheimers Dis, vol. 55, no. 2, pp. 823-833, 2017.
, “Validation of a Latent Construct for Dementia in a Population-Wide Dataset from Singapore.”, J Alzheimers Dis, vol. 55, no. 2, pp. 823-833, 2017.
, “Validation of a Latent Construct for Dementia in a Population-Wide Dataset from Singapore.”, J Alzheimers Dis, vol. 55, no. 2, pp. 823-833, 2017.
, “Validation of a Multivariate Prediction Model of the Clinical Progression of Alzheimer's Disease in a Community-Dwelling Multiethnic Cohort.”, J Alzheimers Dis, vol. 95, no. 1, pp. 93-117, 2023.
, “Validation of a Multivariate Prediction Model of the Clinical Progression of Alzheimer's Disease in a Community-Dwelling Multiethnic Cohort.”, J Alzheimers Dis, vol. 95, no. 1, pp. 93-117, 2023.
, “Validation of Immunoassay-Based Tools for the Comprehensive Quantification of Aβ40 and Aβ42 Peptides in Plasma.”, J Alzheimers Dis, vol. 54, no. 2, pp. 751-62, 2016.
, “Validation of microRNAs in Cerebrospinal Fluid as Biomarkers for Different Forms of Dementia in a Multicenter Study.”, J Alzheimers Dis, vol. 52, no. 4, pp. 1321-33, 2016.
, “Validation of Plasma Proteomic Biomarkers Relating to Brain Amyloid Burden in the EMIF-Alzheimer's Disease Multimodal Biomarker Discovery Cohort.”, J Alzheimers Dis, vol. 74, no. 1, pp. 213-225, 2020.
, “Validation of Plasma Proteomic Biomarkers Relating to Brain Amyloid Burden in the EMIF-Alzheimer's Disease Multimodal Biomarker Discovery Cohort.”, J Alzheimers Dis, vol. 74, no. 1, pp. 213-225, 2020.
, “Validation of Plasma Proteomic Biomarkers Relating to Brain Amyloid Burden in the EMIF-Alzheimer's Disease Multimodal Biomarker Discovery Cohort.”, J Alzheimers Dis, vol. 74, no. 1, pp. 213-225, 2020.
, “Validation of Plasma Proteomic Biomarkers Relating to Brain Amyloid Burden in the EMIF-Alzheimer's Disease Multimodal Biomarker Discovery Cohort.”, J Alzheimers Dis, vol. 74, no. 1, pp. 213-225, 2020.
, “Validation of Plasma Proteomic Biomarkers Relating to Brain Amyloid Burden in the EMIF-Alzheimer's Disease Multimodal Biomarker Discovery Cohort.”, J Alzheimers Dis, vol. 74, no. 1, pp. 213-225, 2020.
, “Validation of Suspected Somatic Single Nucleotide Variations in the Brain of Alzheimer's Disease Patients.”, J Alzheimers Dis, vol. 56, no. 3, pp. 977-990, 2017.
,